Refining endpoints in brain tumor clinical trials
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2012/03/27
-
Journal
-
Indian UGC (journal)
-
Refrences15
-
Citations35
-
Christina A. Meyers
-
Edwin P. Rock
-
Howard A. Fine
Cite
Meyers, Christina A., et al. “Refining Endpoints in Brain Tumor Clinical Trials”. Journal of Neuro-Oncology, vol. 108, no. 2, 2012, pp. 227-30, https://doi.org/10.1007/s11060-012-0813-8.
Meyers, C. A., Rock, E. P., & Fine, H. A. (2012). Refining endpoints in brain tumor clinical trials. Journal of Neuro-Oncology, 108(2), 227-230. https://doi.org/10.1007/s11060-012-0813-8
Meyers, Christina A., Edwin P. Rock, and Howard A. Fine. “Refining Endpoints in Brain Tumor Clinical Trials”. Journal of Neuro-Oncology 108, no. 2 (2012): 227-30. https://doi.org/10.1007/s11060-012-0813-8.
1.
Meyers CA, Rock EP, Fine HA. Refining endpoints in brain tumor clinical trials. Journal of Neuro-Oncology. 2012;108(2):227-30.
Journal Categories
Medicine
Internal medicine
Neoplasms
Tumors
Oncology
Including cancer and carcinogens
Medicine
Internal medicine
Neurosciences
Biological psychiatry
Neuropsychiatry
Medicine
Internal medicine
Neurosciences
Biological psychiatry
Neuropsychiatry
Neurology
Diseases of the nervous system
You May Also Like
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012
- Angiogenesis and invasion in glioma
- Genetic profile of astrocytic and oligodendroglial gliomas
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Primary Analysis of a Phase II Randomized Trial Radiation Therapy Oncology Group (RTOG) 0212: Impact of Different Total Doses and Schedules of Prophylactic Cranial Irradiation on Chronic Neurotoxicity and Quality of Life for Patients With Limited-Disease Small-Cell Lung Cancer | International Journal of Radiation Oncology*Biology*Physics |
| 179 | 2011 |
| Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab | Neuro-Oncology |
| 80 | 2011 |
| 10.1016/S1470-2045(10)70294-1 | The Lancet Oncology |
| 2011 | |
| Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines | Annals of Oncology |
| 121 | 2007 |
| 10.1200/JCO.2005.04.6086 | 2006 |
Refrences Analysis
The category
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 3
is the most frequently represented among the references in this article. It primarily includes studies from Neuro-Oncology and The Lancet Oncology. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Financial toxicity of radiotherapy for multiple brain metastases: Will it get worse or better? | Neuro-Oncology Practice |
| 2023 | |
| The burden of a brain tumor: guiding patient centric care in neuro-oncology | Journal of Neuro-Oncology |
| 4 | 2022 |
| Pre- and postoperative self-reported and objectively assessed neurocognitive functioning in lower grade glioma patients | Journal of Clinical Neuroscience |
| 2022 | |
| Functional outcome and quality of life after meningioma surgery: a systematic review | Acta Neurologica Scandinavica |
| 9 | 2021 |
The Impact of Stereotactic or Whole Brain Radiotherapy on Neurocognitive Functioning in Adult Patients with Brain Metastases: A Systematic Review and Meta-Analysis | Oncology Research and Treatment |
| 15 | 2021 |
Citations Analysis
The category
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 20
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Measuring Clinical Benefit: Use of Patient-Reported Outcomes (PRO) in Primary Brain Tumor Clinical Trials and was published in 2012. The most recent citation comes from a 2023 study titled Financial toxicity of radiotherapy for multiple brain metastases: Will it get worse or better?. This article reached its peak citation in 2019, with 5 citations. It has been cited in 24 different journals, 12% of which are open access. Among related journals, the Journal of Neuro-Oncology cited this research the most, with 7 citations. The chart below illustrates the annual citation trends for this article.